Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Recursion is currently generating limited revenue through partnerships with larger pharmaceutical leaders like Merck and ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look ...